Richard Weisler, MD


University of North Carolina at Chapel Hill


  • Consultant: Alcobra Pharma; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb; Dainippon Sumitomo Pharma America, Inc./Sunovion; Forest Laboratories, Inc.; Ingenuity Health; Otsuka America Pharmaceutical, Inc.; ProPhase Labs, Inc.; Shire Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Validus Pharmaceuticals LLC
  • Research Support: Alcobra Pharma; Bristol-Myers Squibb; Dainippon Sumitomo Pharma America, Inc./Sunovion; Elan; Hoffmann-La Roche Inc.; Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Shire Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.
  • Speakers Bureau: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb; Dainippon Sumitomo Pharma America, Inc./Sunovion; Merck & Co., Inc.; Novartis Pharmaceutical Corporation; Otsuka America Pharmaceutical, Inc.; Shire Pharmaceuticals, Inc.; Validus Pharmaceuticals LLC
  • Stock or Equity: Cortex Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer Inc.
Copyright © 2015 - American Academy of Child Adolescent Psychiatry. All Rights Reserved.